Search

Now showing items 1-7 of 7

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Nature Research , 2022 , Article)

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; Yassine, Hadi M.; ... more authors ... less authors ( Nature Research , 2022 , Article)

There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other ...

Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

Suelen H., Qassim; Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Elsevier , 2023 , Article)

BackgroundWaning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination ...

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; ... more authors ... less authors (2021 , Article)

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

Laith J., Abu-Raddad; Chemaitelly, Hiam; Coyle, Peter; Malek, Joel A.; Ahmed, Ayeda A.; ... more authors ... less authors ( Elsevier , 2021 , Article)

Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months

Laith J., Abu-Raddad; Chemaitelly, Hiam; Malek, Joel A.; Ahmed, Ayeda A.; Mohamoud, Yasmin A.; ... more authors ... less authors ( Elsevier , 2021 , Article)

We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or ...

Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar

R. Hasan, Mohammad; K.R. Kalikiri, Mahesh; Mirza, Faheem; Sundararaju, Sathyavathi; Sharma, Anju; ... more authors ... less authors ( Elsevier , 2021 , Article)

Complementing whole genome sequencing strategies with high-throughput multiplex RT-qPCR genotyping allows for more comprehensive and real-time tracking of SARS-CoV-2 variants of concern. During the second and third waves ...